Literature DB >> 23403321

TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy.

Sabina Chiaretti, Fulvia Brugnoletti, Simona Tavolaro, Silvia Bonina, Francesca Paoloni, Marilisa Marinelli, Nancy Patten, Massimiliano Bonifacio, Maria Grazia Kropp, Simona Sica, Anna Guarini, Robin Foà.   

Abstract

Entities:  

Keywords:  TP53 mutations; adult acute lymphoblastic leukemia; response to induction chemotherapy

Mesh：

Substances：

Year:  2013        PMID： 23403321      PMCID： PMC3640132          DOI： 10.3324/haematol.2012.076786

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Cancer. p53, guardian of the genome.

Authors:  D P Lane
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

2.  Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood.

Authors:  M Wada; C R Bartram; H Nakamura; M Hachiya; D L Chen; J Borenstein; C W Miller; L Ludwig; T E Hansen-Hagge; W D Ludwig
Journal:  Blood       Date:  1993-11-15       Impact factor: 22.113

3.  Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Authors:  Jinghui Zhang; Charles G Mullighan; Richard C Harvey; Gang Wu; Xiang Chen; Michael Edmonson; Kenneth H Buetow; William L Carroll; I-Ming Chen; Meenakshi Devidas; Daniela S Gerhard; Mignon L Loh; Gregory H Reaman; Mary V Relling; Bruce M Camitta; W Paul Bowman; Malcolm A Smith; Cheryl L Willman; James R Downing; Stephen P Hunger
Journal:  Blood       Date:  2011-06-16       Impact factor: 22.113

4.  Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia.

Authors:  M Kawamura; H Ohnishi; S X Guo; X M Sheng; M Minegishi; R Hanada; K Horibe; T Hongo; Y Kaneko; F Bessho; M Yanagisawa; T Sekiya; Y Hayashi
Journal:  Leuk Res       Date:  1999-02       Impact factor: 3.156

5.  TP53 mutation and survival in chronic lymphocytic leukemia.

Authors:  Thorsten Zenz; Barbara Eichhorst; Raymonde Busch; Tina Denzel; Sonja Häbe; Dirk Winkler; Andreas Bühler; Jennifer Edelmann; Manuela Bergmann; Georg Hopfinger; Manfred Hensel; Michael Hallek; Hartmut Döhner; Stephan Stilgenbauer
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

Review 6.  TP53 in hematological cancer: low incidence of mutations with significant clinical relevance.

Authors:  Shoshana Peller; Varda Rotter
Journal:  Hum Mutat       Date:  2003-03       Impact factor: 4.878

Review 7.  Acute lymphoblastic leukaemia.

Authors:  Ching-Hon Pui; Leslie L Robison; A Thomas Look
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

8.  Frequent p53 mutation in relapsed acute lymphoblastic leukemia with cytogenetic instability: a longitudinal analysis.

Authors:  J L Tang; H F Tien; M T Lin; P J Chen; Y C Chen
Journal:  Anticancer Res       Date:  1998 Mar-Apr       Impact factor: 2.480

9.  p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies.

Authors:  E Wattel; C Preudhomme; B Hecquet; M Vanrumbeke; B Quesnel; I Dervite; P Morel; P Fenaux
Journal:  Blood       Date:  1994-11-01       Impact factor: 22.113

10.  Mechanisms of relapse in acute leukaemia: involvement of p53 mutated subclones in disease progression in acute lymphoblastic leukaemia.

Authors:  Y M Zhu; L Foroni; I G McQuaker; M Papaioannou; A Haynes; H H Russell
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640
View more
  24 in total

1.  MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia.

Authors:  Courtney L Jones; Christy M Gearheart; Susan Fosmire; Cristina Delgado-Martin; Nikki A Evensen; Karen Bride; Angela J Waanders; Faye Pais; Jinhua Wang; Teena Bhatla; Danielle S Bitterman; Simone R de Rijk; Wallace Bourgeois; Smita Dandekar; Eugene Park; Tamara M Burleson; Pillai Pallavi Madhusoodhan; David T Teachey; Elizabeth A Raetz; Michelle L Hermiston; Markus Müschen; Mignon L Loh; Stephen P Hunger; Jinghui Zhang; Michael J Garabedian; Christopher C Porter; William L Carroll
Journal:  Blood       Date:  2015-08-31       Impact factor: 22.113

2.  Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia.

Authors:  Sankaranarayanan Kannan; Marisa J L Aitken; Shelley M Herbrich; Leonard S Golfman; Mandy G Hall; Duncan H Mak; Jared K Burks; Guangchun Song; Marina Konopleva; Charles G Mullighan; Joya Chandra; Patrick A Zweidler-McKay
Journal:  Mol Cancer Ther       Date:  2019-06-21       Impact factor: 6.261

3.  LMO2 activation by deacetylation is indispensable for hematopoiesis and T-ALL leukemogenesis.

Authors:  Tatsuya Morishima; Ann-Christin Krahl; Masoud Nasri; Yun Xu; Narges Aghaallaei; Betül Findik; Maksim Klimiankou; Malte Ritter; Marcus D Hartmann; Christian Johannes Gloeckner; Sylwia Stefanczyk; Christian Lindner; Benedikt Oswald; Regine Bernhard; Karin Hähnel; Ursula Hermanutz-Klein; Martin Ebinger; Rupert Handgretinger; Nicolas Casadei; Karl Welte; Maya Andre; Patrick Müller; Baubak Bajoghli; Julia Skokowa
Journal:  Blood       Date:  2019-07-31       Impact factor: 22.113

4.  TP53, ETV6 and RUNX1 germline variants in a case series of patients developing secondary neoplasms after treatment for childhood acute lymphoblastic leukemia.

Authors:  Stefanie V Junk; Norman Klein; Sabine Schreek; Martin Zimmermann; Anja Möricke; Kirsten Bleckmann; Julia Alten; Elif Dagdan; Gunnar Cario; Christian P Kratz; Martin Schrappe; Martin Stanulla
Journal:  Haematologica       Date:  2019-07-09       Impact factor: 9.941

5.  Mutations of TP53 gene in adult acute lymphoblastic leukemia at diagnosis do not affect the achievement of hematologic response but correlate with early relapse and very poor survival.

Authors:  Silvia Salmoiraghi; Marie Lorena Guinea Montalvo; Greta Ubiali; Manuela Tosi; Barbara Peruta; Pamela Zanghi; Elena Oldani; Cristina Boschini; Alexander Kohlmann; Silvia Bungaro; Tamara Intermesoli; Elisabetta Terruzzi; Emanuele Angelucci; Irene Cavattoni; Fabio Ciceri; Renato Bassan; Alessandro Rambaldi; Orietta Spinelli
Journal:  Haematologica       Date:  2016-03-18       Impact factor: 9.941

6.  RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.

Authors:  Valentina Gianfelici; Sabina Chiaretti; Sofie Demeyer; Filomena Di Giacomo; Monica Messina; Roberta La Starza; Nadia Peragine; Francesca Paoloni; Ellen Geerdens; Valentina Pierini; Loredana Elia; Marco Mancini; Maria Stefania De Propris; Valerio Apicella; Gianluca Gaidano; Anna Maria Testi; Antonella Vitale; Marco Vignetti; Cristina Mecucci; Anna Guarini; Jan Cools; Robin Foà
Journal:  Haematologica       Date:  2016-05-05       Impact factor: 9.941

7.  PHF6 regulates hematopoietic stem and progenitor cells and its loss synergizes with expression of TLX3 to cause leukemia.

Authors:  Helen M McRae; Alexandra L Garnham; Yifang Hu; Matthew T Witkowski; Mark A Corbett; Mathew P Dixon; Rose E May; Bilal N Sheikh; William Chiang; Andrew J Kueh; Tan A Nguyen; Kevin Man; Renee Gloury; Brandon J Aubrey; Antonia Policheni; Ladina Di Rago; Warren S Alexander; Daniel H D Gray; Andreas Strasser; Edwin D Hawkins; Stephen Wilcox; Jozef Gécz; Axel Kallies; Matthew P McCormack; Gordon K Smyth; Anne K Voss; Tim Thomas
Journal:  Blood       Date:  2019-02-12       Impact factor: 22.113

8.  TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.

Authors:  Rashmi Kanagal-Shamanna; Preetesh Jain; Koichi Takahashi; Nicholas J Short; Guilin Tang; Ghayas C Issa; Farhad Ravandi; Guillermo Garcia-Manero; Cameron C Yin; Rajyalakshmi Luthra; Keyur P Patel; Joseph D Khoury; Guillermo Montalban-Bravo; Koji Sasaki; Tapan M Kadia; Gautam Borthakur; Marina Konopleva; Nitin Jain; Rebecca Garris; Sherry Pierce; William Wierda; Zeev Estrov; Jorge Cortes; Susan O'Brien; Hagop M Kantarjian; Elias Jabbour
Journal:  Cancer       Date:  2017-06-13       Impact factor: 6.860

9.  LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors.

Authors:  Ying Cheng; Kudakwashe Chikwava; Chao Wu; Haibing Zhang; Anchit Bhagat; Dehua Pei; John K Choi; Wei Tong
Journal:  J Clin Invest       Date:  2016-03-14       Impact factor: 14.808

Review 10.  Diagnosis and subclassification of acute lymphoblastic leukemia.

Authors:  Sabina Chiaretti; Gina Zini; Renato Bassan
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-11-01       Impact factor: 2.576
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.